NICE now backs both Repatha and Praluent

The U.K.'s NICE issued final appraisal determinations (FADs) recommending the use of PCSK9 inhibitors Praluent alirocumab and

Read the full 172 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE